As of 01 December 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] and (2) Lenvatinib [4 mg/10 mg capsule] for adults diagnosed with advanced continue reading : HTA Council Preliminary Recommendation on (1) Atezolizumab + Bevacizumab and (2) Lenvatinib for Adults Diagnosed with Advanced or Unresectable Hepatocellular Cancer (HCC)
HTA Council Preliminary Recommendation on Thermal Ablation for the Treatment of Premalignant Lesions of the Cervix among Women 30 to 65 years old
As of 19 November 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of Thermal Ablation for the treatment of premalignant lesions of the cervix among women 30 to 65 years old who are deemed eligible for ablation in accordance to the World Health Organization (WHO) screen-treat approach or screen-triage-treat continue reading : HTA Council Preliminary Recommendation on Thermal Ablation for the Treatment of Premalignant Lesions of the Cervix among Women 30 to 65 years old
HTA Council Preliminary Recommendation on Japanese Encephalitis Vaccine (JEV)
Update as of 13 June 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Japanese encephalitis vaccine for the prevention of Japanese encephalitis among children 9 to 59 months old in high risk areas ended on 10 June 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final continue reading : HTA Council Preliminary Recommendation on Japanese Encephalitis Vaccine (JEV)
HTA Council Preliminary Recommendation on ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS)
Update as of 21 May 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS) ended on 19 May 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to continue reading : HTA Council Preliminary Recommendation on ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS)
HTA Council Preliminary Recommendation on Hexavalent Vaccine for active immunization of infants to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to Haemophilus influenzae type b
As of 05 March 2025, the Health Technology Assessment (HTA) Council makes public its preliminary recommendation on the non-inclusion in the PNF and thus the non-government financing of hexavalent vaccine, for stakeholder feedback/comments. Overall, the HTA Council recognizes that hexavalent vaccines will result in a simpler immunization schedule and thus, better compliance and easier implementation. continue reading : HTA Council Preliminary Recommendation on Hexavalent Vaccine for active immunization of infants to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to Haemophilus influenzae type b